Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738195 | 0.89 | TSHR (0.59) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL1681567 | 0.87 | TSHR (0.61) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL26187833 | 0.85 | TSHR (0.63) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL2022785 | 0.85 | TSHR (0.63) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL308812 | 0.85 | TSHR (0.63) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL23321852 | 0.84 | TSHR (0.62) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL3628945 | 0.83 | TSHR (0.61) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9064667 | 0.83 | TSHR (0.61) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL23322173 | 0.82 | TSHR (0.66) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL23321864 | 0.82 | TSHR (0.66) | TSHRALDH1A1CYP3A4HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2930177-B1 | PREPARATION OF SILAZANE COMPOUND | SHINETSU CHEMICAL CO (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9416147-B2 | Preparation of silazane compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-16 | — | — | US | disclosed |
| EP-2930177-A1 | Preparation of silazane compound | Shin-Etsu Chemical Co., Ltd. (JP) | 2015-10-14 | — | — | EP | disclosed |
| US-20150284414-A1 | PREPARATION OF SILAZANE COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284414-A1 | PREPARATION OF SILAZANE COMPOUND | SLTM, SKP2, BCAT2 | TSHR 4559/4885ALDH1A1 2132/4885CYP3A4 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.